No Data
No Data
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $47 to $140
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $77 to $140
Ultragenyx Pharmaceutical Analyst Ratings
Piper Sandler Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Ultragenyx Pharmaceutical (RARE)